The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation
A successful kidney transplantation of an HLA sensitized patient has been accomplished following desensitization with the candidate drug IdeS at Uppsala University Hospital. The patient is enrolled in the ongoing Phase II study sponsored by Hansa Medical with the primary objective to study IdeS’ capacity to reduce levels of anti-HLA antibodies in sensitized patients.HLA sensitized patients rarely become transplanted due to the immediate risk of transplant rejection caused by donor specific anti-HLA antibodies. However, following treatment with IdeS the now transplanted patient became
